The Life Sciences team advised Royalty Pharma plc (Nasdaq: RPRX) on a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals, and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly — directly when it when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when i acquires existing royalties from the original innovators.
The Goodwin transactions team was led by Robert Crawford, Catherine Magazu, Jacqueline Mercier, Jo-an Chen, and Alison Liou. The Goodwin IP team was led by Carl Morales, Colm Murphy, Srikanth Reddy, Kuwabo Mubyana, Maria Smith, and Steven Cuss. Barry Bazian provided bankruptcy and restructuring support for the transaction.
For more information on the deal, please read the press release.